Navigation Links
Favrille Announces Resolution of Debt Obligations and Plans for Maximizing Assets
Date:7/7/2008

cility and other assets over the past few weeks," said John P. Longenecker, Ph.D., President and Chief Executive Officer of Favrille. "The future direction of the Company going forward remains uncertain but could include either a reorganization which might involve in-licensing of products contingent upon additional financing, a merger with another entity or liquidation of the Company either inside or outside of bankruptcy. We will continue to explore the relative benefits of all these options. The management and board of directors of Favrille remain committed to addressing these issues and maximizing the value of our assets as expeditiously as possible."

About Favrille, Inc.

Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system.

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Favrille's product candidates, proprietary technologies and research and clinical development programs. Such forward- looking statements involve known and unknown risks, uncertainties and other factors that may cause Favrille's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to Favrille's ability to continue its operations, conserve cash or recognize value on our assets and additional risks discussed in Favrille's filings with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement. Favrille is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements containe
'/>"/>

SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
2. Favrille CEO to Present at Bear Stearns Healthcare Conference
3. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
4. Favrille to Present at BIO InvestorForum
5. Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007
6. Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
7. Favrille Announces $21.1 Million Registered Direct Offering
8. Favrille Reports Fourth Quarter and Year End 2007 Financial Results
9. Favrille to Host Conference Call and Live Webcast to Discuss First Quarter 2008 Financial Results on May 8, 2008
10. Favrille Reports First Quarter 2008 Financial Results
11. Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with Follicular B-Cell Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 19, 2014 Research and Markets  has announced the ... Strategic Business Report" report to their offering. ... Supplies in US$ Thousands by the following Product Segments: Media, Sera, ... the US, Canada , Japan ... and Latin America . Annual estimates and forecasts ...
(Date:8/19/2014)... Aug. 19, 2014 Research and Markets  has ... (SOFCs) - Global Strategic Business Report" report to their ... for Solid Oxide Fuel Cells (SOFCs) in US$ Thousands. The ... Canada , Europe , ... forecasts are provided for the period 2012 through 2020. Market ...
(Date:8/19/2014)... 19, 2014 Research and ... the "Spectroscopy Equipment and Accessories - ... their offering. This report ... and Accessories in US$ Thousands by the ... Raman Spectrometers, NMR-EPR Spectrometers, Near Infrared (NIR) ...
(Date:8/19/2014)... 2014   Synthetic Biologics, Inc. (NYSE ... biologic and drug programs targeting specific pathogens that ... its novel C. difficile development program ... Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), ... Synthetic Biologics, Senior Vice President, ...
Breaking Biology Technology:Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 4
... NEW YORK, Sept. 7 Richard Gabriel, Chief,Executive ... DNAG),( http://www.dnaprint.com ) will be featured in an ... to take place on September 10 at 11,a.m. ... http://www.wallst.net by 8 p.m.,EDT on September 10. ...
... Inc. (Nasdaq: HGSI ) announced today that its ... New York will be webcast,and may be accessed at ... A member of Human Genome Sciences, senior management ... September 11, 2007 at 4:00 pm,Eastern Time. Investors ...
... Appeared More Effective Than rituximab ... in a ... GEN) announced today that ofatumumab (HuMax-CD20(R)) appeared more,effective at inducing ... in a pre-clinical study. The CD20,antibodies were incubated with tumor ...
Cached Biology Technology:WallSt.net (www.wallst.net) Announces Upcoming Interview With CEO of DNAPrint Genomics 2Genmab Announces Encouraging Preclinical Data for ofatumumab 2
(Date:8/19/2014)... August 19, 2014A new ovoid structure discovered in the ... contains a variety of minerals, and shows evidence of ... melting of the permafrost and mixing of surface and ... range of analytical studies to determine the origin of ... how this ovoid formed, point to the most likely ...
(Date:8/19/2014)... analyzed concentrations of African dust transported to South ... spring. These research findings offer new insight on ... of African dust, including the climate change-induced human ... increased African dust emissions in the coming decades., ... School of Marine and Atmospheric Science and colleagues ...
(Date:8/19/2014)... This news release is available in French . ... Stand: balancing the BENEFITS and RISKS of physical activity ... a stand on the promotion of childhood physical activity ... Applied Physiology, Nutrition, and Metabolism ( APNM ... of knowledge in the area of risk of physical ...
Breaking Biology News(10 mins):Life on Mars? Implications of a newly discovered mineral-rich structure 2Study of African dust transport to South America reveals air quality impacts 2Taking a stand: Balancing the BENEFITS and RISKS of physical activity in children 2Taking a stand: Balancing the BENEFITS and RISKS of physical activity in children 3
... may trigger the development of schizophrenia and other bipolar ... Faculty of Biological Sciences (UK) has shown that the ... these disorders by affecting the production of dopamine - ... aspects of movement, cognition and behaviour. Toxoplasmosis, which ...
... in genes which can result in changes in the ... associated with susceptibility to common diseases. In a new ... the Association for Psychological Science, psychologist Tina B. Lonsdorf ... and the University of Greifswald in Germany examined the ...
... fluoride (SO 2 F 2 ), a gas commonly used to ... that remains in the atmosphere about 36 years, six to 10 ... by Jens Mhle, an atmospheric chemist at Scripps Institution of Oceanography, ... the gas rose at a rate of 4 to 6 percent ...
Cached Biology News:Research supports toxoplasmosis link to schizophrenia 2The genetics of fear: Study suggests specific genetic variations contribute to anxiety disorders 2Termite killer lingers as a potent greenhouse gas 2Termite killer lingers as a potent greenhouse gas 3
Normal human serum, single donor...
... Quality ISO 9001:2000 Certified ... All Precedures Validated, SOP's Training ... Process for All Procedures GLP Documentation Upon ... one stop shopping point for all your ...
Human IL-17D Affinity Purified Polyclonal Ab...
BBS/Glycerol/Casein Block and Diluent - 10X Concentrate, 1 L...
Biology Products: